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CObjectives: Productivity costs constitute a substantial proportion of
the total societal costs associated with cancer. We compared the re-
sults of applying two different analytical methods—the traditional hu-
man capital approach (HCA) and the emerging friction cost approach
(FCA)—to estimate breast and prostate cancer productivity costs in Ire-
land in 2008. Methods: Data from a survey of breast and prostate can-
cer patients were combined with population-level survival estimates
and a national wage data set to calculate costs of temporary disability
(cancer-related work absence), permanent disability (workforce depar-
ture, reduced working hours), and premature mortality. Results: For
reast cancer, productivity costs per person using the HCA were
193,425 and those per person using the FCA were €8,103; for prostate
ancer, the comparable estimates were €109,154 and €8,205, respec-
ively. The HCA generated higher costs for younger patients (breast
ancer) because of greater lifetime earning potential. In contrast, the
CA resulted in higher productivity costs for older male patients (pros- O
h
Irela
al So
oi:10.1016/j.jval.2011.12.012ate cancer) commensurate with higher earning capacity over a shorter
ime period. Reduced working hours postcancer was a key driver of
otal HCA productivity costs. HCA costs were sensitive to assumptions
bout discount and growth rates. FCA costs were sensitive to assump-
ions about the friction period. Conclusions: The magnitude of the
stimates obtained in this study illustrates the importance of including
roductivity costs when considering the economic impact of illness.
astly different results emerge from the application of the HCA and the
CA, and this finding emphasizes the importance of choosing the study
erspective carefully and being explicit about assumptions that under-
in the methods.
eywords: burden of illness, cancer, friction cost approach, human cap-
tal approach, productivity costs.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cost-of-illness studies aim to describe the economic burden of a
disease on society. By providing information on this burden in
monetary terms, such studies can identify key cost drivers to aid
resource allocation. A holistic approach to cost estimation neces-
sitates the capture of both direct costs and indirect costs. A recent
report by the Economist Intelligence Unit [1] derived a global eco-
nomic cost of US$286 billion for new cancer cases in 2009, 24% of
which resulted from productivity losses. Thus, studies that fail to
compute indirect costs, particularly productivity losses, may se-
verely underestimate the true opportunity costs of a disease.
Recently, there has been increasing recognition of the impact
of cancer on employment and, hence productivity. The global bur-
den of cancer is substantial, with 12.7 million new cases diagnosed
in 2008 and 7.6 million cancer deaths [2]. Breast cancer and pros-
tate cancer account for 10.9% and 7.2% of all newly diagnosed
cancer cases, respectively. Individuals diagnosed with cancer are
less likely to be employed than unaffected individuals [3]. The
ajority of those diagnosed and who were working at the time of
iagnosis have to take some time away from work, typically to
ndergo treatment or recover from associated side effects [4]. The
eriod of absence ranges from a few weeks to many months [5–7].
* Address correspondence to: Paul Hanly, National Cancer Registry
reland.
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098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.Most will return to the workforce but may work reduced hours
[8,9]. This may occur by choice, because of a reduction in a survi-
vor’s productive capacity or, by employer imposition [10–12]. A
proportion never returns to the workforce because of mortality or
a decision to substitute work for increased leisure time perma-
nently.
In economic terms, cancer-related productivity losses emanate
from morbidity and premature mortality costs. Traditionally, mor-
bidity costs include short-term cancer-related work absences, in
addition to permanent absences associated with workforce depar-
ture. Premature mortality costs comprise the extra loss of life di-
rectly attributed to the disease and the related reduction in poten-
tial productive capacity. Despite this relatively straightforward
delineation of component parts, the appropriate method to mea-
sure and value the productivity costs associated with a disease
remains an area of considerable debate [13–17].
The cancer literature to date is dominated by the use of the
uman capital approach (HCA) [18–23]. This approach encom-
passes a societal perspective and estimates an individual’s contri-
bution to society by applying labor force earnings as a measure of
productivity. It assumes full employment in competitive labor
markets with minimum transaction costs [24]. Firms are regarded
as profit maximizers employing workers until the marginal reve-
nue product of labor equals the wage rate. Under these conditions,
nd, Building 6800, Cork Airport Business Park, Kinsale Road, Cork,
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and so an opportunity cost exists until the age of retirement. Crit-
ics argue that the neoclassical assumptions underpinning the
method are unrealistic [24]. In practice, positive unemployment
evels exist and the replacement of workers occurs on an ongoing
asis; thus, the approach may overestimate productivity costs.
The friction cost approach (FCA), by contrast, takes an employ-
r’s perspective and attempts to measure “actual” rather than “po-
ential” output loss, by assuming that costs relate solely to the
eriod of time necessary to reestablish the initial production level
i.e., the friction period) and workers leaving employment are re-
laced by unemployed workers at an extremely low opportunity
ost [25]. Critics of the FCA [15] argue that it moves away from the
axioms underpinning the neoclassical theory of the firm [16]. Fur-
thermore, it assumes that vacancies are filled by previously unem-
ployed individuals either directly or at the end of a chain of vacan-
cies, meaning that the calculation of costs for a single, typically
short, friction period may result in underestimation [24].
The primary aim of this study was to extend the current limited
evidence base by comparing the results of applying two different
analytical methods—the HCA and the FCA—to quantifying the
productivity costs of an illness. To illustrate this, we used the ex-
ample of breast and prostate cancer in Ireland, the most common
cancers in females and males, respectively. In contrast to previous
productivity cost studies [19,26], we adopted a bottom-up ap-
proach based on a survey of breast and prostate cancer patients to
facilitate detailed quantification of productivity loss subcompo-
nents.
Material and Methods
This article describes one component of a larger project investi-
gating the financial and economic impact of cancer in Ireland [4].
The current study encompassed both a societal (HCA) and an em-
ployer’s (FCA) perspective, estimating lifetime productivity costs
per patient with newly diagnosed primary invasive breast cancer
(International Statistical Classification of Diseases, 10th Revision, code
C50) or prostate cancer (International Statistical Classification of Dis-
eases, 10th Revision, code C61) who were working (either employed
or self-employed) at the time of diagnosis. Costs are expressed in
2008 values, and presented in euros for breast and prostate cancer
separately. In the base-case analysis, future costs were discounted
at 4% as recommended for Ireland [27].
Data sources
A postal questionnaire was distributed to breast and prostate can-
cer survivors during June to October 2008. Full details are provided
elsewhere [4]. Briefly, in March 2008, a population-based sample of
1373 survivors was selected from the National Cancer Registry
Ireland and invited to complete a questionnaire. Survivors were
between 6 months and 2 years since diagnosis and had been
treated at 1 of 17 hospitals across the country (14 mixed public/
private, 3 private). Employment-focused questions included
whether the individual was working at the time of diagnosis,
whether he or she took time off work because of cancer, and whether
this absence was of a temporary or permanent nature. We also re-
quested hours worked on average pre- and postdiagnosis. We re-
ceived 740 completed questionnaires, yielding a response rate of
54%. Of these, 358 respondents (250 with breast cancer and 108
with prostate cancer) indicated that they were in some form of
employment at the time of diagnosis.
National breast and prostate cancer registration data were
used to estimate premature mortality and permanent disability
(PD) costs (see below). Several other national sources provided
additional data. The Central Statistics Office’s “National employ-
ment survey 2007” [28] supplied data on gross earnings, stratifiedby gender and age, while the Central Statistics Office’s “Employee
skills, training and job vacancies survey 2006” [29] provided job
vacancy duration data. Forecasted gross domestic product growth,
a proxy for labor productivity growth, was obtained from the “Re-
covery scenarios for Ireland: an update” published by the Eco-
nomic and Social Research Institute [30].
Estimation methods
The HCA assumes that an individual produces a stream of output
over a lifetime and generated labor earnings reflect productive
capacity [24]. Estimation requires applying a relevant wage rate to
time foregone from productive activity. We applied gross earnings
stratified by age and gender to time estimates. Estimation of the
FCA requires a measure of the assumed friction period, an esti-
mate of elasticity of annual labor time versus annual labor produc-
tivity (the proportion of reduction in effective labor time resulting
from an absence from work, which might be 1 because of, for
example, a firm’s internal labor reserves), and values for the lost
production of employees. We estimated a friction period of 11.3
weeks on the basis of the average vacancy duration in 2006 (7.3
weeks), plus an additional 4 weeks to account for the lagged nature
of a job advertisement following permanent absenteeism (2
weeks) and the duration necessary for the uptake of a position
following a successful application (2 weeks). The second 2-week
period also accounts for the training period necessary for a re-
placement worker. In the absence of an accurate estimate of the
elasticity of annual labor time versus average labor productivity in
Ireland, we assumed a base case of 1 and changed this in the
sensitivity analysis (see below). Cost due to absence from work
was valued by gross earnings stratified by age and gender.
Indirect cost components
Productivity costs were decomposed into four subcomponents: 1)
losses arising from temporary disability (TD) due to short-term
cancer-related work absences, 2) losses due to PD in the form of
workforce departure, 3) losses due to PD in the form of reduced
hours, and 4) losses due to premature mortality.
Temporary disability
TD estimates were based on our survey of prostate and breast
cancer patients. Following the HCA, we estimated TD as time ab-
sent from work for each patient (taken as the product of the num-
ber of weeks absent from work and the average number of hours
worked per week before diagnosis) multiplied by the age- and gen-
der-adjusted gross earnings, measured before the deduction of
tax, Pay Related Social Insurance, and superannuation, payable by
organizations to their employees.
Friction costs due to TD were calculated similarly, but with the
length of absence restricted to the friction period. Temporary ab-
sences that extended beyond this time period were capped at 11.3
weeks. Shorter absences were estimated as fractions of 11.3 weeks
following Hutubessy et al. [31]. For example, an absence of 5 weeks
incurred a cost of 5/11.3. Following Wieser et al. [32], we applied
weights to gross foregone wages as follows: 0.8 for primary educa-
tion, 1 for secondary education, and 1.2 for tertiary education.
Permanent disability: workforce departure
The percentage of PD cases was based on our patient survey. Un-
der the HCA, workforce departure entails a productivity cost to the
economy that lasts until the age of retirement (assumed 65 years
of age in the Irish case). Irish wage rate growth was approximated
by forecasted gross national product (GNP) growth (a proxy for
productivity growth) in the economy at 2.6%. We multiplied age-
and gender-adjusted gross earnings by the annual number of
hours worked in the prediagnosis period to establish a base 2008
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number of years remaining until retirement for each individual,
accounting for wage growth and the discount rate. The estimate
for each patient was adjusted to account for potential double
counting with premature mortality costs as follows.
Annual age-specific survival probabilities in the absence of
cancer were derived from 2006 national life tables [33], for age at
diagnosis to age 65 years. These probabilities were modified to
account for relative survival probabilities of breast and prostate
cancer patients [34], using national cancer registrations. Because
breast and prostate cancer survival probabilities for single-year
ages are unstable, relative survival was computed for broader age
groups for cases diagnosed during 2005 to 2008, and averaged over
10 years because long-term relative survival curves for breast and
prostate cancer show a constant excess mortality hazard [35]. For
example, the adjustment factor applied to PD costs in the first year
postdiagnosis for a woman diagnosed with breast cancer at age 60
years was computed as follows. The expected survival rate of a
60-year-old woman to age 61 years was 0.994; breast cancer pa-
tients aged 55 to 64 years had, on average, an annual relative sur-
vival probability of 0.974 during the first 10 years of follow-up, and
so the adjustment was 0.994  0.974  0.969. Beyond 10 years,
adjustment factors were calculated assuming that 1) cancer-re-
lated reductions in survival continued to apply (i.e., 0.974 in this
example) or 2) survival returned to background levels derived from
national life tables for Ireland, with the average of 1) and 2) applied
to patient data.
Under the FCA, the friction period acts as a threshold for PD
costs. In cases in which a respondent indicated a PD due to cancer,
we computed 11.3 weeks of productivity loss by using age- and
gender-adjusted gross earnings.
Permanent disability: reduced hours
By using data from our patient survey, we calculated HCA produc-
tivity costs due to reduced working time by applying annual age-
and gender-adjusted gross earnings until the retirement age to the
reduction in working hours reported. Assumptions about eco-
nomic growth and adjustments for double counting were made as
before.
Under the FCA, in cases in which patients were absent from
work for less than the friction period, but returned to work with
reduced hours, the productivity cost of reduced working time was
computed for the portion of the friction period remaining after
adjusting for TD. For example, if a patient returned to work after a
5-week absence and reduced his or her hours of work thereafter by
10 hours per week, the cost for the 10 hours of lost work per week
was valued up until the termination of the 11.3-week vacancy pe-
riod (i.e., for 6.3 weeks).
Premature mortality
Following the HCA, we assumed that without cancer, the produc-
tive capacity of an individual would continue from the age of di-
agnosis until age 65 years. Projected average loss of years (pre-65)
for each patient in the survey was computed by estimating the
probability of “excess” (cancer-related) mortality annually to age
65 years (having subtracted expected/background mortality), ap-
plying this to the number of patients at risk at each age, weighting
the results by the number of years remaining, and then summing
(similar to the PD adjustment factors above, the midpoint of “10-
year cure” and “no-cure” scenarios was used). Projected years of
life lost were multiplied by the average discounted and wage
growth–adjusted, age- and gender-adjusted, annual gross earn-
ings for the remainder of the cancer patient’s working life to gen-
erate monetary estimates. Under the FCA, the calculation of pre-
mature mortality costs followed the same approach, but with
costs confined to the friction period.Sensitivity analyses
We conducted various sensitivity analyses to determine the sen-
sitivity of the results to key assumptions inherent in the analysis.
For the HCA, we varied GNP growth and discount rates; for the
FCA, we varied the friction period, labor elasticity, and the educa-
tion level. A GNP growth rate of 0% was applied to establish the
sensitivity of estimates to labor productivity growth and account
for the continued reduction in growth forecasts in the Irish econ-
omy. The base-case discount rate of 4% was varied to 0% and 6%.
Uncertainty in the friction period was accounted for by rerunning
the analysis for friction periods of 7 and 15 weeks. The elasticity
for annual labor time versus labor productivity estimate was var-
ied from 1 in the base case to 0.8 in the sensitivity analysis. No
published estimate of the elasticity for annual labor time versus
labor productivity exists for Ireland; therefore, 0.8 was chosen in
line with previous productivity studies [31,36,37]. Finally, we as-
sumed a common level of education, with all individuals assigned
an education weighting of 1.
Results
Table 1 presents summary statistics for the survey of breast and
prostate cancer patients. There were notable differences between
the cancers. Men with prostate cancer tend to be older at diagnosis
(58 years vs 49 years), but they take considerably less time off work
postdiagnosis than do women with breast cancer. Also, the per-
centage of men with prostate cancer who took temporary work
absences following diagnosis was lower than that for female
breast cancer patients. The rate of permanent workforce depar-
ture and reduced working hours was similar for the two cancers.
Table 2 summarizes, separately for breast and prostate cancer,
lifetime per person costs of lost productivity according to the HCA
and the FCA. HCA estimates of total productivity costs were 1.8
times higher for breast cancer (€193,425) than for prostate cancer
(€109,154). Much of this difference in total costs was driven by
premature mortality costs, which were 4 times higher for breast
cancer than for prostate cancer and accounted for 44% of the total
costs for breast cancer compared with 19% for prostate cancer.
This divergence is due to prostate cancer patients being closer to
retirement age than are breast cancer patients at diagnosis. The
absolute TD cost for breast cancer was approximately double that
for prostate cancer, but the percentage of total costs accounted for
was similar. The subcategories of PD (workforce departure and
reduced hours) accounted for a larger percentage of the total for
prostate cancer than for breast cancer, although the absolute costs
were not dissimilar.
The results are rather different when the FCA is considered.
Under this approach, the costs associated with prostate cancer
(€8205) slightly exceeded those for breast cancer (€8103). In each of
the cost subgroups, with the exception of premature mortality,
prostate productivity costs were higher than breast productivity
costs. In contrast to the HCA estimates, the dominant cost cate-
gory under the FCA was TD (accounting for 73% and 77% of the
total for breast and prostate cancer, respectively), followed by pre-
mature mortality (14%) for breast cancer and workforce departure
(16%) for prostate cancer. PD reduced hours made only a very mod-
est contribution to total costs.
Table 2 also presents a direct comparison of the two ap-
proaches, with FCA estimates expressed as a percentage of the
relevant HCA estimates. For breast cancer, the FCA total produc-
tivity cost estimate amounted to 4.2% of the equivalent HCA esti-
mate. For prostate cancer, it was 7.5%. The TD estimate revealed
the highest proportion of productivity costs captured by the FCA
compared with the HCA because of its short-term nature. FCA
estimates associated with premature mortality, PD: reduced
rce fo
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HCA equivalents.
Sensitivity analysis
Table 3 (also Fig. 1A, B in Supplemental Materials found at doi:
10.1016/j.jval.2011.12.012) presents the sensitivity analyses for the
HCA. Varying the discount rate and GNP growth rate estimates did
not alter the relative ranking of breast or prostate cancer costs, but
it did have a greater impact on breast cancer estimates than on
prostate cancer estimates. Compared with base-case values, esti-
mates varied by a maximum of 42% for breast cancer and 24% for
prostate cancer (under the scenario of 0% discount and 2.6%
growth).
Table 4 (also Fig. 2 in Supplemental Materials found at doi:
10.1016/j.jval.2011.12.012) presents the results of the sensitivity
analyses for the FCA. An increase in the friction period from 11.3 to
15 weeks increased total productivity costs by around one-third,
slightly more for breast cancer than for prostate cancer, and
changed the relative ranking, with breast cancer associated
with a higher productivity cost than prostate cancer. A reduc-
tion to 7 weeks reduced total productivity costs by around one-
Table 1 – Descriptive statistics for sample of breast and pro
Statistic Breast
Sample size 25
Median diagnosis age (y) 4
Age category numbers (y)
45 6
45 and 50 6
50 and 55 5
55 and 60 2
60 4
Percentage of temporary disability cases 9
Average time taken off work following diagnosis 44.9
Percentage of permanent disability cases:
reduced hours*
2
Average weekly reduction in hours following a
return to work
5.5 h
Percentage of permanent disability cases:
workforce departure†
1
* Respondents who indicated return to work with reduced hours.
† Respondents who indicated permanent departure from the workfo
Table 2 – Average per person productivity costs (euros) for
capital approach (HCA) and the friction cost approach (FCA
Breast cancer costs (€)
Productivity cost categories HCA FCA
Disability costs
Temporary disability costs 26,363 (13.6%) 5,929 (73.2%)
Permanent disability: workforce
departure costs
33,043 (17.1%) 988 (12.2%)
Permanent disability: reduced
hours costs
49,534 (25.6%) 26 (0.3%)
Total disability costs 108,939 (56.3%) 6,943 (85.7%)
Premature mortality costs 84,486 (43.7%) 1,160 (14.3%)
Total productivity costs* 193,425 (100.0%) 8,103 (100.0%)* Cost subcomponents may not exactly equal the total because of roundinthird. Changing the elasticity of labor time to labor productivity
by one-fifth translated directly into a reduction of one-fifth in
total costs. Varying the assumption about educational level had
very little effect on the estimated total productivity costs for
either cancer.
Discussion
The current study shows that different approaches to productivity
cost estimation produce very different results: the HCA produces
much (13–24 times) higher productivity cost estimates than does
the FCA. The reason for this lies in the different economic perspec-
tives (i.e., society [HCA] vs. employer [FCA]) and, consequently, the
disparate time frames (i.e., remainder of the individual’s working
life [HCA] vs. short time until the individual is replaced [FCA])
associated with the approaches. Results also revealed a range of
other factors that were prominent in influencing the cost esti-
mates produced by the two approaches. These factors are dis-
cussed in the following subsections.
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Under the HCA, total productivity costs for breast cancer exceeded
those for prostate cancer, while under the FCA, the opposite was
true. In our sample, 50% of the breast cancer patients were aged 50
years or younger, whereas the median age of the prostate cancer
patients was 58 years, with only 7% of the sample aged 50 years or
younger. This difference served to highlight the importance of age
in determining productivity costs, particularly when using the
HCA. Under the HCA, higher costs were associated with younger
workers whose lifetime earning potential would be severely re-
duced by cancer (i.e., breast cancer patients). Premature mortality,
in particular, caused by a diagnosis of breast cancer led to an ac-
cumulation of productivity losses over a, on average, longer lost
future stream of potential working life, thus resulting in signifi-
cantly higher total costs under the HCA for breast cancer than for
prostate cancer.
Gender differences in wages intertwined with the effects of age
to impact on productivity costs. In Ireland, on average, females
earn 25% less than do males between the ages of 15 and 60 years,
with the gender divergence increasing with age; for example, in
2007, females between the ages of 15 and 24 years earned 17% less
than did an equivalently aged male, whereas a female aged be-
tween 50 and 59 years earned 38% less on average [38]. These
ifferentials tempered the effect of (younger) age on the HCA es-
imates: the difference between the HCA estimates for the two
ancers would have been expected to be even larger if both af-
ected men. For example, although similar proportions of breast
nd prostate cancers left the workforce permanently, the associ-
Table 3 – Sensitivity analysis for the human capital approa
and prostate cancer patients in 2008, according to differen
cost for each scenario reported as percentage variation fro
0%
Growth 0%
Breast 216,278 (11.8%)
Prostate 117,238 (7.4%)
Growth 2.6% (base case)
Breast 275,099 (42.2%)
Prostate 135,813 (24.4%)
* Base-case estimates are shown in boldface.
Table 4 – Sensitivity analysis for the friction cost approach
prostate cancer patients in 2008, according to different ass
education level, with costs for each scenario reported as pe
LP†  1 and edu‡  weig
Friction period 7 wk
Breast 5,235 (35.4%)
Prostate 5,651 (31.1%)
Friction period 11.7 wk (base case)
Breast 8,103 (100.0%)
Prostate 8,205 (100.0%)
Friction period 15 wk
Breast 10,579 (30.6%)
Prostate 10,433 (27.2%)
* Base-case estimates are shown in boldface.
† LP, Elasticity of annual labor time versus average labor productivit
‡ edu, Education level.ated HCA average productivity costs for these cost subcompo-
nents were similar for breast and prostate cancer, despite the
younger age of the former.
Because of the limited time period imposed by the FCA, costs
were dictated by current wage levels acting as a proxy for produc-
tivity levels. Thus, the FCA produced higher productivity costs for
workers who earned higher wages—that is, older men, in this in-
stance prostate cancer patients. Almost 50% of prostate cancer
patients in the sample were aged between 50 and 59 years, the age
at which male wages per hour peak [38]; thus absences, even of a
temporary nature, engendered considerable productivity costs.
Female wages per hour were well below their male equivalents
across every age cohort; therefore, absences restricted to the fric-
tion period did not offer enough time for cost accumulation to
compensate for higher male wage rates.
Overall, differentials in the age of the affected cases and in
earnings by gender explained the difference in the relative rank of
breast and prostate cancer costs under the two methods.
Drivers of productivity costs: length of illness
Average productivity costs per patient according to the HCA were
in the order of 24 times larger for breast cancer and 13 times larger
for prostate cancer compared with the equivalent FCA estimates.
In addition to being influenced by age, gender, and wages, this
differential is accounted for by the long-term effects of cancer.
Cancer is increasingly becoming recognized as a chronic condi-
tion, which, for those in employment at the time of diagnosis, can
verage per person productivity costs (euros) for breast
umptions for the growth rate and the discount rate, with
se-case estimate*.
Discount rate
4% (base case) 6%
160,533 (17.0%) 142,369 (26.4%)
96,358 (11.7%) 88,553 (18.9%)
193,425 (100.0%) 167,948 (13.2%)
109,154 (100.0%) 99,392 (8.9%)
rage per person productivity costs (euros) for breast and
tions for the friction period, labor elasticity, and
tage variation from base-case estimate*.
bor elasticity and education level
LP  0.8 and edu  weighted LP  1 and edu  1
4,186 (48.3%) 4,863 (40.0%)
4,519 (44.9%) 5,694 (30.6%)
6,480 (20.0%) 7,524 (7.2%)
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8,460 (4.4%) 9,821 (21.2%)
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434 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 2 9 – 4 3 6engender lengthy absences from work; these lengthy absences
translate into high HCA costs compared with FCA costs. For ill-
nesses that are episodic in nature, for example, neck pain [39] and
back pain [31], the differential between productivity estimates ob-
tained from the two approaches was smaller.
Cost subcomponents
An examination of differences in cost subcomponent estimates,
including premature mortality costs, PD: reduced hours costs, and
PD: workforce departure costs sheds further light on the method-
ological differences between the approaches. Each category fol-
lowed the potential stream of productivity losses to retirement in
the case of the HCA but became 0 in the FCA upon cessation of the
friction period.
The principal difference between HCA breast and prostate can-
cer productivity costs was due to premature mortality costs, which
were higher for breast cancer than for prostate cancer due to the
lower age of diagnosis and potential for accumulated losses over
time. Although estimates derived from the FCA maintained this
relative difference, premature mortality was less significant in ab-
solute terms.
TD costs were considerably higher for breast cancer than for
prostate cancer according to the HCA. This was due to the much
longer average period of cancer-related work absence for breast
cancer than for prostate cancer found in our survey (44.9 weeks vs.
13.9 weeks), a finding echoed elsewhere [6]. When the effects of TD
were limited to the friction period, the difference between sites
was much less; indeed, the TD estimate for prostate cancer ex-
ceeded the figure for breast cancer because of higher wages for
older prostate patients.
In addition to illustrating key differences between the HCA and
the FCA, our study extends the traditional productivity cost cate-
gories of TD, PD, and premature mortality to include a measure of
the weekly reduction in work hours experienced by some return-
ing cancer patients. Termed PD: reduced hours, examination of
this factor elucidates a previously gray area in the literature. Un-
der the HCA, PD: reduced hours costs emerged as the largest com-
ponent of productivity losses for prostate cancer (accounting for
37% of total costs) and the second largest for breast cancer (26% of
total costs). Failure to capture these costs would have resulted in a
substantial underestimation of total productivity loss under the
HCA (although the importance of these costs was much dimin-
ished upon application of the FCA). Given that substantial propor-
tions of cancer patients in Ireland and elsewhere reduce their
working hours postdiagnosis [7–9], future studies (particularly
those that apply the HCA) should consider these costs.
Sensitivity analyses
Perhaps unsurprisingly, FCA estimates were rather sensitive to
the assumptions about the length of the friction period. Given the
variable nature of the friction period over time and its reliance on
existing macroeconomic conditions, estimates of lost productivity
costs in other settings, or in the same setting but under altered
economic conditions, are likely to be very different. For instance,
our estimate of the friction period was based on a survey of vacan-
cies in the Irish labor market in 2006 with an unemployment rate
of 4.4% (the closest estimate available to when the cases in the
sample were diagnosed). Currently, unemployment stands at
14.3% [40]. Such a large increase in unemployment tends to de-
crease job vacancy duration and the associated friction period,
and, as suggested by the sensitivity analysis, even a relatively
modest change in the friction period can have a substantial effect
on FCA cost estimates. Eliminating the education weighting in the
wage data changed the results relatively little, but education level
represents only a proxy measure for friction period variability
across different sectors. More accurate measurements of thisbased, for example, on sector-specific vacancy estimates would be
worth incorporating in future studies.
Comparisons with studies of cancer and other conditions,
and generalizibility
This study emphasizes the importance of examining indirect costs
when considering the economic impact of illness. These costs ac-
count for a considerable proportion of total costs arising from a
diagnosis of cancer but have received relatively little attention in
the literature. A few studies from North America have considered
the productivity costs associated with all cancers [19,41,42]. Al-
though these studies revealed the fundamental importance of
productivity costs, direct comparison between them is problem-
atic because of differences in assumptions, time periods, cost cat-
egories, and the mix of cancers included.
As our study has shown, stratification of costs pertaining to
individual cancer sites enhances knowledge of specific cost driv-
ers. Despite this, only a few studies have used the HCA to estimate
productivity costs for individual cancers [18,21–23]. In terms of
breast cancer specifically, Lidgren et al. [18] found that indirect
osts accounted for 70% of total breast cancer costs in Sweden in
002. Mortality costs accounted for 37%, followed by sick leave at
1% and early retirement at 13%. Broekx et al. [23] supported these
ndings through an incidence-based bottom-up study of breast
ancer costs in Flanders where morbidity and premature mortality
ccounted for 89% of total costs. We are not aware of any previous
tudies of prostate cancer productivity costs using the HCA.
There have been even fewer studies using the FCA. The only
ther cost-of-illness study in English, as far as we are aware, to
irectly compare cancer estimates obtained from the HCA and the
CA related to cervical and breast cancers in Spain [26]. The au-
hors found, for breast cancer, that total FCA estimates were 4% of
he HCA equivalent, an estimate similar to the 4.2% in the current
tudy. Decomposition revealed 2% for premature mortality, 3.4%
or PD, and 23.7% for TD compared with 1.4%, 3.0%, and 22.5% in
he current study. These authors did not consider PD: reduced
ours costs.
Studies that evaluated illnesses other than cancer and em-
loyed the FCA were consistent with ours in that their estimates of
roductivity costs were much smaller than those generated by
sing the HCA [14,32,43,44], but the relative difference between
he estimates varied by condition. For rheumatoid arthritis and
nkylosing spondylitis, HCA estimates were 3 to 10 times higher
han FCA estimates [44]; for cardiovascular disease, HCA estimates
ere 35 times higher [43]; and for schizophrenia, they were 69
imes higher [25]. As we have shown, the difference between the
stimates produced by the two methods is due to a range of factors
ncluding patient age, gender, length of work absence, and level of
orkforce departure; risk of premature mortality is also likely to
e important.
As we have also revealed, it is likely that the generalizibility of
esults of studies that have used the FCA is somewhat limited,
ecause the estimates are so heavily dependent on the length of
he friction period and the macroeconomic conditions (e.g., unem-
loyment, sector, and gender-specific wages) in the study setting.
CA estimates are less impacted by unemployment levels and the
roader state of the macroeconomy, and are therefore more likely
o be comparable from study to study.
Strengths and limitations
In addition to comparing the HCA and the FCA, the major
strengths of this study were as follows: the combination of data
from a survey of breast and prostate cancer patients with national
routine data; the inclusion of two cancer sites (which served to
reveal key differences in the two productivity costing approaches);
and the valuation of a previously overlooked productivity cost
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important driver of total lost productivity costs in this study.
We derived our patient sample from the National Cancer Reg-
istry Ireland. The registry has greater than 98% completeness [45],
which should have helped minimize selection bias. The 54% re-
sponse rate, which could be considered reasonably high given the
potentially intrusive nature of the survey topic, can be viewed as a
potential limitation. This, together with the relatively small sam-
ple size, means we cannot exclude the possibility of some partic-
ipation bias. We could not compare characteristics of respondents
and nonrespondents because survey responses were completely
anonymous, but we could compare key characteristics with the
total population of relevant cancer patients. The ratio of breast to
prostate cancer respondents (2.5:1) was somewhat higher than the
ratio among incident cases aged less than 65 years in the popula-
tion (approx 2:1), probably a result of the higher response among
breast cancer cases (58% vs. 47%). In addition, the median age at
diagnosis among survey participants was slightly lower than for
all breast and prostate cancers diagnosed under the age of 65 years
in Ireland (breast: sample 49 years, population 52 years; pros-
tate: sample  58 years, population  59 years). This may have
resulted in slight overestimation of HCA costs.
Although the characteristics of participants were similar to
those of the population of patients, it is possible that respondent’s
reported work absences were different from those at the popula-
tion level. The cross-sectional nature of the survey is another po-
tential limitation, but data on typical workforce absences among
cancer patients [6] means that we would have expected the ma-
jority of patients to have reestablished, or established new, work-
ing patterns by the time of survey completion. However, we can-
not exclude the possibility that had the survey been conducted at
another time point, the resulting estimates would have differed.
The costs reported here are specific to employed individuals due to
a lack of data on unpaid labor. Although this entails considerable
equity implications, it is the standard approach in many indirect
cost studies [26,31,32].
Estimating the friction period remains an area of uncertainty.
The best estimate that we could obtain derived from a survey
conducted in 2006 [29], which just preceded the recent major
transformation in Irish labor dynamics. FCA estimates may be
underestimated if the assumption that vacancies created by long-
term absences are filled by previously unemployed individuals is
contravened; we did not identify appropriate data to enable us to
assess the effects of this. For absences shorter than the friction
period, we chose to follow others [31] and evaluate costs solely for
the fraction of the friction period affected. This may be inappro-
priate in some contexts. For example, if an employer is legally
bound to provide sick pay to absent workers, the cost to the em-
ployer will include both the lost productivity of the absent worker,
or the cost of a replacement worker, and the cost of the sick pay.
Employers in Ireland, however, are not legally obliged to compen-
sate absent workers due to illness.
Further work is required in the area of PD: reduced working
hours. Our estimate of reduced working hours following diagnosis
was assumed to apply until age 65 years under the HCA. Some of
the patients, perhaps following a full recovery, may increase their
working hours over time, while others, particularly those experi-
encing a recurrence, may reduce their hours even further, or leave
the workforce completely. However, there is only limited data in
the literature on such longer-term effects (see, e.g., Bradley et al.
[9]) and no data from Ireland. Further longitudinal studies of can-
cer patients over time would aid in overcoming this uncertainty.
Recently, employers and the research community have be-
come concerned with the costs of presenteeism [46,47], which re-
fers to reduced on-the-job productivity engendered by acute or
chronic illness. Cancer patients often suffer from cognitive or
physical impairments that can lead to a reduction in on-the-jobproductivity [48,49]. We did not have the data necessary to esti-
mate costs of presenteeism here; consequently, our total indirect
costs may be underestimated. The estimation of presenteeism
costs, however, is not trivial, and various methodological issues,
including the correct valuation method, remain to be resolved
[46,47].
Future implications
Because cost-of-illness studies underpin many aspects of health
care decision making and expenditure allocation, it is important to
have robust estimates of both direct and indirect costs incurred by
specific illnesses. The issue remains one of how best to estimate
indirect costs and integrate them into the total cost of an illness.
The productivity costs associated with cancer were 96% lower for
breast cancer and 93% lower for prostate cancer according to the
FCA than the HCA. While this may suggest that the economic
burden of productivity costs of cancer is less significant than pre-
viously considered, it seems most likely that the value of produc-
tivity costs lies somewhere between these two extremes. The HCA
measures potential productivity losses; however, it could be ar-
gued that the assumptions underpinning the method are unreal-
istic, particularly in an economic climate of high unemployment,
and that the approach tends to overestimate the economic burden
of illnesses. While the FCA claims to measure actual losses, it also
has several flaws including the difficulty in obtaining reliable data
to inform the calculations (e.g., friction periods for different pop-
ulation subgroups and productivity losses due to hiring, replacing,
and training new employees). In addition, the method is limited by
the lack of econometric models examining longer-term effects,
and a dearth of evidence on empirical estimates of the number of
friction periods created by long-term absenteeism caused by ill-
ness. Thus, the FCA probably underestimates productivity costs. If
the FCA is to establish itself as the primary measure of productiv-
ity costs, further work is needed to clarify these issues and to deal
with the challenge of the geographical and time-specific nature of
the FCA estimates. For now, the simplicity of the HCA may offer
more benefits in terms of transparency and comparability, al-
though estimates should be treated cautiously and interpreted
correctly as the “potential” productivity losses of a disease.
Conclusions
The HCA and the FCA adopt different perspectives and, conse-
quently, accumulate costs over different time frames. By looking
at two cancer sites, this study served to reveal further important
differences between the approaches. The HCA produced a higher
productivity cost for breast cancer than for prostate cancer. With
the application of the FCA, the reverse was true: the cohort of older
males affected by prostate cancer resulted in relatively higher pro-
ductivity costs. The divergence reflected the different age profile
for these cancers and gender disparities in average earnings.
Moreover, a key driver of costs was PD due to reduced working
hours, which remains an understudied concept in the productivity
literature. Overall, this study illustrates the importance of exam-
ining indirect costs when considering the economic impact of ill-
ness, including a range of productivity cost subcomponents in
such estimates, choosing the costing perspective carefully, and
being explicit about assumptions that underpin the methods.
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